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Eleven (1.8%) of 597 patients underwent ophthalmic
surgery within 1 month before the onset of prion disease or
after the onset. All ophthalmologists reused surgical instru-
ments that had been incompletely sterilized to eliminate
infectious prion protein. Ophthalmologists should be aware
of prion diseases as a possible cause of visual symptoms
and use disposable instruments whenever possible.
V
isual impairment occurs in 10% to 20% of patients
with sporadic Creutzfeldt-Jakob disease (sCJD) dur-
ing an early stage of the disease (Heidenhain variant) (1,2).
Some patients with prion diseases may visit ophthalmolo-
gists with visual impairment due to prion diseases or with
coexisting age-related eye diseases (3,4).
Infectious prion protein (PrPSc) was identified in the
retina and optic nerve in patients with variant CJD (vCJD)
and sCJD (5,6), and CJD has been transmitted by corneal
transplantation (7,8). In the World Health Organization
(WHO) guidelines, eyes were classified as highly infec-
tious tissues (9).
Secondary transmission of PrPSc through ophthalmic
surgery could possibly be prevented around the onset of
prion diseases, although surgery that is performed long
before the onset of prion diseases would not have that
potential. It is important to understand the current status of
ophthalmic surgery for patients with prion diseases and to
clarify the clinical features of the patients with prion dis-
eases who undergo ophthalmic surgery. Here, we describe
the relevant data from CJD surveillance in Japan.
The Study
We analyzed the patients with prion diseases who had
been registered by the CJD Surveillance Committee in
Japan from April 1999 through March 2005. We prospec-
tively investigated each patient with a surveillance proto-
col that assembled information about life history, previous
medical history, clinical history, laboratory data, and
results of molecular genetic and pathologic analyses.
Written consent, approved by the Institutional Ethics
Committee, was obtained from all the patients’ families;
members of the Surveillance Committee examined the
patients and collected the data.
We classified the patients into 4 categories: sCJD,
infectious prion diseases, inherited prion diseases, and
unclassified prion diseases. sCJD was diagnosed according
to the classical criteria established by Masters et al. (10).
Infectious prion diseases included CJD associated with
cadaveric dura mater graft (dCJD) or other iatrogenic
opportunities for prion infection, in which the criteria for
sCJD were applied for the diagnosis, and vCJD, in which
the diagnosis was based on WHO criteria (2001) (11).
Regarding the accuracy of the diagnosis of inherited prion
diseases, cases verified by pathology report were defined
as definite, and cases with mutations in the prion protein
gene and neuropsychiatric manifestations compatible with
prion diseases were defined as probable.
Among patients with a history of ophthalmic surgery,
we directed special attention to the patients who had a his-
tory of eye surgery within 1 month before the obvious onset
of prion disease or after the onset. Because the onset of
prion diseases often overlaps with various kinds of prodro-
mal symptoms, determining the precise time point of onset
is difficult; therefore, we included the period of 1 month
before the obvious onset. To gather information about the
ophthalmic surgery, we mailed questionnaires to the oph-
thalmologists who operated on these patients, requesting
the following information: diagnosis of ophthalmologic
diseases, surgical procedures performed, changes in the
symptoms after the surgery, whether the instruments were
reused, and methods of cleaning reused instruments. 
To ascertain the clinical features of prion diseases, we
analyzed the patient’s age at onset and duration of disease
course, which was calculated as the interval between the
onset and the appearance of the akinetic mutism state or
death in the patients who died without akinetic mutism.
Among early clinical manifestations of prion diseases,
dementia and visual disturbance are major determinants
that would influence the indication for ophthalmic surgery,
so we grouped the patients according to whether they had
dementia or visual impairment within 2 months after onset
of symptoms.
The sex distribution of the patients who had oph-
thalmic surgery around the time of onset of clinical symp-
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Japantoms and those who did not was compared by Fisher exact
tests, and differences in age at onset and disease duration
were compared by Mann-Whitney U tests. We used χ2
tests to compare the distribution of the patients with or
without dementia or visual impairment within 2 months of
onset. Statistical significance was defined as p<0.05.
We found 597 patients with definite or probable diag-
nosis of prion diseases: 468 (78.4%) with sCJD; 78
(13.1%) with inherited prion diseases; 48 (8.0%) with
infectious prion diseases, including 47 cases of dCJD; and
1 patient with vCJD and 3 patients with unclassified CJD.
Thirty-seven patients (6.2%) had a history of oph-
thalmic surgery at some time in their lives. Among them,
11 patients (1.8%) underwent ophthalmic surgery within 1
month before the obvious onset of prion disease or after
the onset. Except for 1 patient with Gerstmann-Sträussler-
Scheinker disease, all of these patients had sCJD. There
have been no reports of the development of prion diseases
in patients who underwent ophthalmic surgery after the
ophthalmic surgery of patients with prion diseases.
Ten patients with sCJD underwent ophthalmic surgery
within 14 months of symptom onset, and 8 of them had
ophthalmic surgery within 4 months of symptom onset
(Table 1). At clinical onset, 4 patients exhibited visual
symptoms, 5 had dementia, and 1 patient had a gait distur-
bance. All patients underwent surgery for cataracts, except
for 1 patient who underwent surgery for a detached retina.
According to the reports on the surgical outcome by the
ophthalmologists of 7 patients, visual disturbance was
unchanged in 2 patients, deteriorated in 1, and improved to
some extent in 4 after surgery. All ophthalmologists reused
some surgical instruments and cleaned instruments by
either autoclaving or the ethylene oxide gas method, which
have been reported to incompletely sterilize PrPSc (9,12).
Clinical features were compared between sCJD
patients who did and did not have ophthalmic surgery
(Table 2). The patients who had ophthalmic surgery had a
significantly longer disease duration than those without
(p=0.0004). Regarding early clinical symptoms within 2
months after onset, the subgroup with visual symptoms
without dementia was significantly overrepresented
among the patients who had ophthalmic surgery compared
with those who did not have surgery (p= 0.0004).
Conclusions
Our study showed that, in 1.8% of the patients with
prion diseases, eye tissues were operated on within 1
month before the obvious onset of prion disease or after
the onset. In addition, the sCJD patients who underwent
surgery had a significantly longer duration of the disease
course as well as significant overrepresentation of visual
symptoms without dementia in the early phase, compared
with patients who did not have ophthalmic surgery.
The prevalence of ophthalmic surgery around the time
of clinical onset of prion diseases in our study is similar to
that (2.0%) in a report from the United Kingdom (13). In
the UK study (13), patients with Heidenhain variant cases
constituted 40% of sCJD patients who had ophthalmic sur-
gery. Early visual impairment (due to prion diseases)
would prompt ophthalmologists to perform surgery.
Currently, cataract surgery is recommended to
improve physical or cognitive function in elderly patients
(14,15). It should be noted that, after performing eye sur-
gery on patients with prion disease, all ophthalmologists
reused surgical instruments that were sterilized with proce-
dures that are incomplete for the sterilization of PrPSc,
although the WHO infection control guidelines for prion
diseases (9) strongly recommend single-use surgical
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sues. The fact that no secondary iatrogenic cases that could
be attributed to surgical procedures were found during our
investigation does not diminish the need for ophthalmolo-
gists to be aware of CJD as a cause of visual symptoms
(including symptoms mimicking those of cataracts) and
highlight the importance of using disposable instruments
whenever possible to avoid cross-contamination.
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